Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From David Wallace
Canadian firm Genix has acquired 30 ophthalmic generic dossiers from Canagen. Genix expects to begin commercialization from 2022.
Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.
Continuing UK price rises were seen for nefopam in January, according to the latest figures from market researcher WaveData.
Meithal Pharmaceuticals has revealed future plans to expand its manufacturing capabilities as the US FDA approved a new vial manufacturing line that will double the firm’s capacity to supply the US market.
Japan’s Towa has almost achieved its full-year operating profit goal in the first nine months of its financial year thanks to lower costs.
The AAM is now searching for new leadership after Chip Davis announced his resignation as president and CEO of the US off-patent industry association.